NCT00354731 is a Phase 3 clinical trial of pentoxifylline in Nephrotic Syndrome, sponsored by National Taiwan University Hospital.

Who is sponsoring NCT00354731?

NCT00354731 is sponsored by National Taiwan University Hospital.

What drugs are being tested in NCT00354731?

Interventions in NCT00354731: pentoxifylline, Corticosteroid.

What condition does NCT00354731 study?

NCT00354731 studies Nephrotic Syndrome.

Is NCT00354731 still recruiting?

NCT00354731 is currently completed. Last updated 12 November 2012.

Last reviewed 2012-11-12 · How we verify

NCT00354731

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Efficacy of Pentoxifylline on Patients With Primary Nephrotic Syndrome

Completed Phase 3 Last updated 12 November 2012

What this trial tests

Phase 3 trial testing pentoxifylline in Nephrotic Syndrome in 62 participants. Completed in 1 April 2011.

Timeline

1 August 2006

Primary endpoint
1 January 2011

1 April 2011

Quick facts

Lead sponsor	National Taiwan University Hospital
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	62
Start date	1 August 2006
Primary completion	1 January 2011
Estimated completion	1 April 2011
Sites	1 location across Taiwan

Drugs / interventions tested

pentoxifylline — full drug profile →
Corticosteroid — full drug profile →

Conditions studied

Nephrotic Syndrome — all drugs for Nephrotic Syndrome →

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 80, any sex, with Nephrotic Syndrome. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

changes from baseline in urinary protein excretion
Time frame: 18 months

Sponsor's own description

We aim to investigate (1) the effects of combined pentoxifylline and corticosteroids, compared to that of corticosteroids, on patients with primary nephrotic syndrome; and if possible (2) the effects of pentoxifylline monotherapy on patients with primary nephrotic syndrome not suitable for or intolerant of standard corticosteroid therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of pentoxifylline

Trials testing the same drug.

NCT05971667 — Effect of Tadalafil, Sildenafil and Pentoxyfylline on Frozen Embryo Transfer Outcomes · Phase 2, PHASE3 · unknown
NCT03476564 — Effects of Pentoxifylline and Vitamin E on Pregnancy Rate in Infertile Women Treated by ICSI: · EARLY_PHASE1 · unknown
NCT03664414 — Pentoxifylline Effect in Patients With Diabetic Nephropathy.(PENFOSIDINE STUDY) · Phase 4 · unknown

Other recruiting trials for Nephrotic Syndrome

Currently open trials in the same condition.

NCT07214818 — SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome · Phase 2, PHASE3 · active not recruiting
NCT06635720 — REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE) · Phase 3 · recruiting
NCT06622915 — Cardiac Performance Evaluation in Children With Steroid Dependent vs Steroid Resistant Nephrotic Syndrome · NA · recruiting
NCT06161701 — Steroid Diabetes in Patients With Kidney Disease · recruiting
NCT06373913 — The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom · recruiting

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00354731 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 12 November 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00354731.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing